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Abstract
Background: The studies reported herein were undertaken to determine if the angiostatic function of p53 could
be exploited as an adjunct to VEGF-targeted therapy in the treatment of renal cell carcinoma (RCC).
Methods: Nude/beige mice bearing human RCC xenografts were treated with various combinations of sunitinib
and the HDM2 antagonist MI-319. Tumors were excised at various time points before and during treatment and
analyzed by western blot and IHC for evidence of p53 activation and function.
Results: Sunitinib treatment increased p53 levels in RCC xenografts and transiently induced the expression of
p21
waf1, Noxa, and HDM2, the levels of which subsequently declined to baseline (or undetectable) with the
emergence of sunitinib resistance. The development of resistance and the suppression of p53-dependent gene
expression temporally correlated with the induction of the p53 antagonist HDMX. The concurrent administration of
MI-319 markedly increased the antitumor and anti-angiogenic activities of sunitinib and led to sustained p53-
dependent gene expression. It also suppressed the expression of the chemokine SDF-1 (CXCL12) and the influx of
CD11b
+/Gr-1
+ myeloid-derived suppressor cells (MDSC) otherwise induced by sunitinib. Although p53 knockdown
markedly reduced the production of the angiostatic peptide endostatin, the production of endostatin was not
augmented by MI-319 treatment.
Conclusions: The evasion of p53 function (possibly through the expression of HDMX) is an essential element in the
development of resistance to VEGF-targeted therapy in RCC. The maintenance of p53 function through the
concurrent administration of an HDM2 antagonist is an effective means of delaying or preventing the development
of resistance.
Keywords: p53, HDM2, HDMX, MI-319, Renal cell carcinoma, Myeloid-derived suppressor cells (MDSC), SDF-1,
Endostatin, Collagen prolyl hydroxylase
Background
One of the major determinants of the response to angio-
genesis inhibitors is the p53 status of the tumor cells. Yu
et al, for example, showed in 2002 that tumors derived
from p53
(+/+) HCT116 colorectal carcinoma cells were far
more sensitive to VEGF receptor targeted therapy than
tumors generated from isogenic p53
(-/-) cells [1]. This
differential sensitivity to treatment correlated with the
in vitro susceptibility of the tumor cells to the pro-
apoptotic effects of hypoxia. Since the publication of these
data over a decade ago, the known range of biologic ef-
fects regulated by p53 has expanded well beyond cell cycle
control and the expression of pro-apoptotic genes to
include such diverse functions as the suppression of
angiogenesis [2]. It is possible that the differential sensitiv-
ity of p53
(-/-) and p53
(+/+) HCT116 tumors to VEGF
receptor-targeted therapy is due to an ability of p53 to
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the tumor microcirculation.
Although the advent of small molecule inhibitors of
VEGFR2 has vastly improved the treatment of patients
with renal cell carcinoma (RCC), the response to these
agents is generally short-lived [3]. The mechanisms by
which tumors ultimately manage to evade the effects of
these agents are numerous and only partly understood
[3-5]. One such mechanism involves the production of
chemokines (e.g. SDF-1, CSF-1, IL-8) that either drive
angiogenesis directly or recruit macrophages and other
myeloid lineage cells, including CD11b
+/Gr-1
+ myeloid-
derived suppressor cells (MDSCs), from the bone marrow
into tumor tissue [5-11]. These cells produce a variety of
factors that promote tumor growth, invasiveness, angio-
genesis, and immunosuppression [10-13]. p53 has been
shown to suppress the expression of SDF-1 [14,15]. Other-
wise, little is known about how the p53 status of a tumor
might affect the extent to which tumors are infiltrated by
MDSC or the facility with which they develop resistance
to VEGF-targeted therapy.
Another mechanism by which p53 suppresses angiogen-
esis is through the induction of genes that modify the
extracellular matrix (ECM). Angiogenesis is negatively
regulated, for example, by several ECM-resident peptides
(e.g. endostatin, canstatin, arresten) which interact with
integrin receptors on the surface of endothelial cells and
suppress their proliferation, survival, and motility [16,17].
These peptides are all derived from the noncollagenous
(NC1) domains of certain types of collagen through the
action of proteases such as MMP9. The genes encoding
the collagen α chains (e.g. COL4A1) from which these
angiostatic peptides are derived as well as that encoding
the prolyl hydroxylase needed for the post-translational
modification and stabilization of collagen [i.e. α(II) PH]
are direct p53 transcriptional targets [18,19]. p53 activa-
tion might therefore be expected to suppress the tumor
microvasculature through the enhanced production of
these peptides. As an illustration of this point, the produc-
tion of arresten, an angiostatic collagen fragment processed
from α1 collagen IV, is markedly diminished in p53
(-/-)
tumor cells and its overexpression has been shown to re-
tard tumor growth and limit angiogenesis [19]. The role
played by these collagen-derived peptides in the regulation
of angiogenesis in RCC and the extent to which their pro-
duction is regulated by p53 is unknown.
p53 levels are generally low in unstressed cells as a re-
sult of HDM2-dependent ubiquitination and proteasomal
degradation [20]. p53 can be activated as a result of
phosphorylation of any of several sites in its N-terminal
domain, which dissociates p53 from HDM2 and en-
hances its stability [21]. Several of the kinases capable of
phosphorylating p53 (e.g. ATM) are redox-sensitive and
capable of activating p53 in the setting of hypoxia [22].
The p53 gene is intact (i.e. neither deleted, mutated, nor
methylated) in most RCC [23]. One might therefore ex-
pect p53 to be activated in RCC subjected to the stress
of angiogenesis inhibition. Several factors, however,
limit the extent, duration, and biological consequences
of p53 activation in these cells. RCC, for example, gen-
erally fail to express p53-dependent genes in response
to DNA damage, presumably due to high constitutive
NF-κB activity [24-26]. The transcriptional activity of p53
is also limited by a member of the POK family (KR-POK)
frequently overexpressed in RCC [27]. This protein
physically interacts with p53 and with the transcrip-
tional corepressors NCoR and BCoR, resulting in reduced
histone H3 and H4 acetylation at the promoters of certain
p53-dependent genes (e.g. p21
waf1/CDKN1A). These
signaling aberrations suggest that p53 might not be able
to contribute to the suppression of angiogenesis or any
other biological process in RCC, despite the integrity of
the p53 gene. Hammond et al, however, have pointed out
that many of the functions of p53 in the setting of hypoxia
are due to transcriptional repression rather than activation
[28-31]. The anti-angiogenic effects of p53, for example,
are in part due to the repression of the miR-17-92
microRNA family [32] and possibly to SDF-1 [14,15] and
it is unclear how these functions would be affected by
constitutive NF-κB activity or KR-POK expression.
Several drugs that inhibit HDM2 are in preclinical or
Phase I trials [33-35]. These drugs offer distinct advan-
tages over conventional chemotherapy in that they are
able to activate p53 in genetically permissive tumor cells
without inducing DNA damage. The studies described in
this paper were undertaken to assess the effects of HDM2
blockade alone and in conjunction with VEGF-targeted
therapies on p53 function, tumor growth, and angiogen-
esis in RCC.
Results
Sunitinib-induced p53 activation in RCC xenografts
To assess the effects of sunitinib treatment on tumor
cell p53 levels and transcriptional activity, 1×10
7 786-0
or A498 cells were implanted subcutaneously into the
flanks of nude/beige mice and the resulting tumors
allowed to grow to a diameter of 10 mm, at which point
sunitinib treatment (50 mg/kg daily) was begun. The
growth of 786-0 xenografts is typically arrested by
sunitinib for a period of only 7-10 days, after which
growth resumes despite the continued administration of
the drug [36]. In the case of A498 xenografts, sunitinib-
induced growth arrest extends to approximately 40 days,
after which the tumors become resistant to treatment.
With each xenograft model, the tumor-bearing mice
were randomly divided into three groups and sacrificed
at one of three time points, after which the tumors were
promptly excised and frozen in liquid N2.O n e - t h i r do f
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when the tumors reached 16 mm in diameter. Half of
the remaining mice were sacrificed at a point when
tumor measurements were stable on treatment (day 3),
and the other half were sacrificed at a point when
sunitinib resistance had developed (tumor size 16 mm).
Tumors were thawed, lysed, and the lysates analyzed
by western blot for p53, and the p53 dependent genes
p21
waf1,H D M 2 ,H D M X ,a n dN O X A .A ss h o w ni n
Figure 1, p53 levels increased markedly in response
to sunitinib administration and remained elevated
throughout the course of treatment in both 786-0 and
A498 xenografts. The p53-dependent genes encoding
p21
waf1 and HDM2 were also induced early during treat-
ment but this effect was transient in that the levels of
both proteins reverted to baseline with the emergence
of drug resistance, despite persistent expression of p53.
NOXA was undetectable in untreated 786-0 and minim-
ally expressed in A498 xenografts. However, in both xe-
nografts, levels rose significantly early during treatment
only to decline with the development of resistance. The
p53 antagonist HDMX was also constitutively present
in A498 and 786-0 xenografts and in both models,
HDMX disappeared from the tumor lysates early during
treatment only to reappear with the development of
resistance. These data suggest that although p53 is
stably induced by sunitinib treatment, its function as a
transcription factor becomes impaired at some time
point during treatment. The data also establish a
temporal link between this loss of p53 function, the
induction of HDMX, and the development of sunitinib
resistance.
Effect of HDM2/HDMX inhibition on tumor growth and
p53 function
To assess the effect of HDM2/HDMX inhibition on tumor
growth, 786-0 and A498 tumors generated as described
above and in Methods were allowed to reach a diameter
of 10 mm. Tumor-bearing mice were then divided into
four treatment groups and treated with either sunitinib
(50 mg/kg), the HDM2/HDMX antagonist MI-319
(200 mg/kg), both drugs, or saline daily by gavage. As
shown in Figure 2A, sunitinib and MI-319 had only a
modest growth-retarding effect on 786-0 xenografts when
the drugs were administered individually. However, the
combination of both drugs actually induced tumor regres-
sion (p<0.0001 combination vs suntinib alone; p<0.0002
vs MI-319 alone). Sunitinib as a single agent had a more
pronounced effect on A498 than on 786-0 xenografts.
MI-319 likewise had single agent activity in this model
and augmented that of sunitinib (p<0.006 combination vs
suntinib alone; p<0.0187 vs MI-319 alone). The basis for
the different responses of these two VHL-deficient RCC
cell lines to treatment is unknown.
In this study, all tumors were removed on day 21 or
when the untreated tumors reached a diameter of 20 mm.
Excised tumors were then divided and one half frozen for
biochemical analysis and the other half paraffin-embedded
for IHC. As shown in Figure 2B, p21
waf1 was undetectable
in the 786-0 tumors from sunitinib alone-treated mice
(despite abundant p53) but readily seen in the tumors
from the dually treated xenografts. HDM2 was detectable
in the tumors from mice treated with MI-319 alone or the
drug combination, but not in those from mice that
received sunitinib alone. In the A498 xenografts, both
p21
waf1 and HDM2 were absent from the sunitinib alone-
treated tumors but abundant in the tumors excised from
mice treated with either MI-319 alone or the sunitinib/
MI-319 combination. HDMX was present in all tumors
except those from the untreated (control) mice. These
data indicate that the concurrent administration of MI-319
is able to maintain the expression of the p53-dependent
genes p21
waf1 and HDM2 despite the presence of HDMX,
suggesting that MI-319 has significant activity against
both HDM2 and HDMX.
Proapoptotic, antiproliferative and antiangiogenic effects
of MI-319
To assess the ability of MI-319 and sunitinib treatment
to induce tumor cell apoptosis, TUNEL assays were
performed on histologic sections of tumors obtained
from mice in the various treatment groups. Sunitinib
(but not MI-319) treatment resulted in a significant
increase in the number of TUNEL-positive cells in both
Figure 1 p53 activation in 786-0 and A498 RCC xenografts
during sunitinib treatment. Lysates were from control (vehicle
only), sunitinib, day 3 (sunitinib responding) and sunitinib, day 21
(suntinib resistant) mice. Lanes represent data from individual
tumors for each treatment group. Blots were probed for p53, and
the p53 dependent genes noxa, hdm2 and p21, as well as hdmx
and vinculin.
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A498) However, MI-319 increased the pro-apoptotic
effect of sunitinib only in 786-0 (p <0.021), but not
A498 xenografts (Figure 3A).
The effects of the two drugs on proliferation were
assessed by Ki-67 staining. Sunitinib treatment increased
the number of cycling cells only in 786-0 xenografts
(p <0.05) and this proliferative effect was blocked by
MI-319 (p< 0.004). As a single agent, MI-319 had no
discernible antiproliferative effect in either 786-0 or
A498 xenografts (Figure 3B).
The antiangiogenic effects of sunitinib and MI-319 were
assessed by IHC using an anti-CD31 antibody. As shown
in Figure 4, both drugs individually induced a marked
decline in microvessel density (MVD) (p<0.0001 for
either drug vs untreated) in both xenograft models and in
786-0 xenografts, the effects of the two drugs were
additive (p<0.0007 for both drugs vs sunitinib).
Effect of MI-319 on sunitinib-induced tumor infiltration
by CD11b
+/Gr-1
+ MDSC
Tumor-infiltrating myeloid-derived suppressor cells
(MDSC) dually expressing CD11b and Gr-1 have been
shown to contribute to the development of resistance to
several forms of treatment, including antiangiogenic
agents that target VEGF receptor signaling [5-11]. To
assess the effects of sunitinib and MI-319 on the accu-
mulation of these cells in tumor tissue, tumors of mice
from the various treatment groups were analyzed by
immunofluorescence. Photographs of the 786-0 slides
are shown in Figure 5A and bar graphs of the data from
both 786-0 and A498 tumors are shown in Figure 5B.
As shown in the figure, very few CD11b
+/Gr-1
+ MDSC
were detected in untreated 786-0 or A498 xenografts.
However, in both xenografts, sunitinib treatment
induced an influx of these cells (p<0.0001 for 786-0,
sunitinib vs untreated; p<0.021 for A498) which was
markedly attenuated by the concurrent administration
of MI-319 (p<0.0001 for 786-0, both drugs vs sunitinib;
p < 0.036 for A498). In the 786-0 model, this suppression
of MDSC tumor infiltration was essentially complete. Of
note, MI-319 did not suppress tumor infiltration by all
myeloid cells as indicated by the persistence of red (but
not magenta) cells in the dually treated tumors. The total
number of CD11b
+ cells present within the tumors was
essentially the same in the sunitinib and sunitinib/MI-319
treatment groups, suggesting that the suppressive effects
of MI-319 were directed at specific subpopulations of
CD11b
+ myeloid cells.
The accumulation of CD11b
+/Gr-1
+ MDSC within
tumor tissue is driven by several chemokines (e.g. SDF-1)
produced by tumor and associated stromal cells [5-11].
The production of the SDF-1 is known to be hypoxia-
induced and negatively regulated by p53 [14,15]. One
would therefore predict that treatment with an angio-
genesis inhibitor such as sunitinib would induce the
expression of SDF-1 and the concurrent administration
of an HDM2 antagonist such as MI-319 might block
this induction. To test this hypothesis, tumor lysates
from the various treatment groups were analyzed by
Figure 2 A). Effects of sunitinib and MI-319 on the growth of 786-0 and A498 xenografts. Tumor volume was normalized to the initial
volume when treatment began for each individual tumor for each treatment group. Each growth curve represents the mean from 6 mice in each
treatment group. B). p53 activation in RCC xenografts. Lysates were from tumors on day 21 after the start of treatment. Lanes represent data from
individual tumors for each treatment group. Blots were probed for p53, and the p53 dependent genes hdm2 and p21, as well as hdmx
and vinculin.
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was not detected in 786-0 tumor lysates from untreated
mice. Sunitinib treatment induced SDF-1 expression, how-
ever, and this induction was completely suppressed by the
concurrent administration of MI-319. In A498 xenografts,
SDF-1 was present constitutively but increased with
sunitinib treatment. As with the 786-0 xenografts, this
induction was suppressed by MI-319.
α(II) prolyl hydroxylase induction by sunitinib: effects of
treatment on endostatin and arresten deposition
α(II) PH is essential for the proper post-translational
modification and stabilization of collagen α chains and for
the production of angiostatic peptides (e.g. endostatin,
canstatin, arresten) from their non-collagenous NC1
domains [18,19]. The gene encoding this enzyme is
p53-dependent. To determine the extent to which p53
activation regulates the deposition of endostatin and
arresten in the ECM of RCC, mice bearing xenografts gen-
erated from 786-0 stably transfected with a tetracycline-
regulable p53 shRNA (see Methods) were treated with
sunitinib with or without the inclusion of doxycycline in
the drinking water. The mice were then sacrificed and the
tumors excised. As shown in Figure 6A, sunitinib treat-
ment was less effective in the absence of p53, especially
during the first few days of treatment (p<0.025 at day 7,
sunitinib alone vs sunitinib+doxycycline). In fact, the
growth curve of the sunitinib+doxycycline-treated mice
overlapped with that of the control mice. Analysis
of tumor lysates showed a complete suppression of
endostatin and arresten production by the tumors that
failed to activate p53 in response to sunitinib (Figure 6B).
These data suggest that p53 activation is essential for the
deposition of endostatin and arresten triggered by the
administration of sunitinib in RCC xenografts.
To determine if the variable p53 function observed
during the course of treatment with sunitinib affected
the levels of α(II) PH, endostatin and arresten, the
tumor lysates from Figure 1 were analyzed by western
blot for these proteins. As shown in Figure 7A and B,
low levels of α(II) PH, endostatin and arresten were
detectable in untreated 786-0 and A498 xenografts, but
all three proteins were up regulated by sunitinib treat-
m e n t .H o w e v e r ,i nc o n t r a s tt op 2 1 ,N o x a ,a n dH D M 2 ,
Figure 3 Effects of treatment on (A and B) apoptosis (tunel) and (C and D) proliferation in RCC xenografts. In both 786-0 (A) and A498
(B) models, sunitinib induced apoptosis as shown by an increase in tunel positive cells. The addition of MI-319 increased apoptosis in 786-0 but
not A498 xenografts. Data is presented as a bar graph showing the mean percent tunel positive cells from six tumors in each treatment group.
Sunitinib treatment increased Ki-67 nuclear staining in 786-0 (C) but not A498 (D) xenografts. The Ki-67 staining in 786-0 xenografts from suntinib
treatment was suppressed in the presence of MI-319. Data is presented as a bar graph showing the mean percent Ki-67 positive cells from six
tumors in each treatment group.
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sistance (Figure 1), endostatin and arresten persisted at
nearly the same level with the onset of drug resistance.
These data suggest that sustained p53 transcriptional
activity is not required to maintain endostatin and
arresten levels in the tumor ECM and that the develop-
ment of resistance cannot be due to a reduction in the
level of these angiostatic peptides.
To determine if HDM2 blockade could increase
endostatin or arresten levels beyond those achieved with
sunitinib alone, 786-0 xenografts were treated with
sunitinib, MI-319, or both drugs and the tumors exam-
i n e db yw e s t e r nb l o t .A ss h o w ni nF i g u r e7 Ca n dD ,t h e
levels of neither endostatin nor arresten were further
increased by the concurrent administration of MI-319
in either 786-0 or A498 xenografts. These data suggest
that the transient activation of p53 induced by sunitinib
treatment in genetically permissive RCC is sufficient to
maximize the deposition of endostatin and arresten in
the ECM. The data also suggest that the superior
antitumor and anti-angiogenic effects of the sunitinib/
MI-319 combination cannot be explained by an increase
in the abundance of these angiostatic collagen fragments
in the ECM. Of note, single agent MI-319 increased
p21
waf1 and arresten levels in A498 xenografts, the only
model of the two evaluated in which the drug had single
agent antitumor activity.
Discussion
Despite the numerous constraints on p53 function in
RCC [24-27], sunitinib treatment does induce the
expression of several p53-dependent genes (e.g. NOXA,
HDM2, p21
waf) in RCC xenografts. The induction of
these genes is, however, limited to the interval during
which tumor growth is suppressed and is attenuated
once resistance develops. Although several factors have
been shown to block p53 transcriptional activity in RCC,
these are for the most part stable genetic alterations
Figure 4 Effects of treatment on microvessel density (MVD) in RCC xenografts. In both (A) 786-0 and (B) A498 models, sunitinib and MI-319
suppressed tumor angiogenesis. In 786-0, the effects of the two drugs were additive. Data is presented as a bar graph showing the mean MVD
from six tumors in each treatment group. A representative tumor section stained for CD31 from each treatment group for 786-0 and A498
xenografts are in C and D, respectively.
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subject to regulation by hypoxia or other metabolic
changes that occur during treatment with angiogenesis
inhibitors.
The factor(s) responsible for the transient activation and
subsequent inactivation of p53 transcriptional activity dur-
ing the course of treatment with sunitinib are unknown
but at least one well-characterized p53 transcriptional
suppressant (i.e. HDMX) appears to be temporally linked
to p53 function in our xenograft models and may there-
fore be a candidate. Unlike its binding partner HDM2,
HDMX is not regulated by p53 [37]. HDMX is constitu-
tively expressed in RCC xenografts but vanishes with the
initiation of sunitinib treatment – along with the appear-
ance of p21
waf. HDMX reappears with the development of
resistance, in association with the down modulation of
p21
waf. These temporal associations strongly implicate
HDMX as the factor responsible for the failure of p53 to
maintain p21
waf1 expression. The reappearance of HDMX
during sunitinib treatment also explains why the suppres-
sion of p53 with an shRNA affected the response of 786-0
xenografts to sunitinib only during the first few days of
treatment. As shown in Figure 6A, the xenografts in
which p53 activation is not impeded characteristically stall
for several days during sunitinib treatment but subse-
quently catch up with those in which p53 expression is
suppressed. These data are consistent with the inactivation
of p53 function by HDMX.
HDMX is physically associated with HDM2 and drugs
that block the interaction between HDM2 and p53 such
as MI-319 also interfere to some extent with the ability of
HDMX to suppress p53 transcriptional activity. The fact
that MI-319 maintains p21
waf levels during sunitinib treat-
ment suggests that the factor responsible for limiting p53
nuclear function most likely interacts with HDM2. This
consideration, in addition to the temporal linkage between
HDMX expression and the absence of p21
waf, supports
the hypothesis that HDMX is the dominant regulator of
p53 nuclear function during sunitinib treatment and pos-
sibly a major factor in the development of drug resistance.
Despite the induction of p21 (Figure 2B), MI-319 treat-
ment does not have a consistent effect on tumor cell
proliferation as determined by Ki67 staining (Figure 3). In
A498 xenografts, for example, MI-319 neither retards pro-
liferation when administered as a single agent or when
given concurrently with sunitinib. In 786-0 xenografts,
however, the addition of MI-319 suppresses the increase
in proliferation induced by sunitinib treatment. The
enhanced tumor cell proliferation induced by sunitinib
is presumably the result of tumor hypoxia, which has
been reported to enhance proliferation in other tumor
models [38].
Figure 5 Effects of treatment on CD11b
+/Gr-1
+ MDSC infiltration into 786-0 and A498 xenografts. A). Immunofluoresence data from 786-0
xenografts. In this study, CD11b=red, Gr-1=blue. Dually expressing cells are magenta colored; tumor nuclei are yellow. B). Bar graph generated
from the manual counting of CD11b
+/Gr-1
+ cells from five individual tumors from each treatment group. Data from both 786-0 and A498
xenografts are shown. C). SDF-1 levels in RCC xenografts. Lysates were from tumors on day 21 after the start of treatment. Lanes represent data
from individual tumors for each treatment group.
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the concurrent administration of MI-319. One mechanism
by which MI-319 might further limit angiogenesis is the
suppression of the influx of MDSC that generally occurs
in response to sunitinib treatment. This suppressive effect
is particularly obvious in 786-0 xenografts, from which
MDSC are virtually excluded by MI-319 treatment. The
means by which MI-319 (and p53) inhibit MDSC traffick-
ing from the bone marrow to tumor tissue is not known
but may involve the suppression of chemokine (e.g. SDF-1)
production by tumor cells and stromal elements that
w e r er e n d e r e dh y p o x i cb yt h ed i s r u p t i o no ft h et u m o r
vasculature. The ability of MI-319 to suppress both
baseline and sunitinib-induced SDF-1 expression in our
RCC xenografts is consistent with the known ability of
p53 to suppress SDF-1 expression [14,15]. Although our
data suggest that the suppression of SDF-1 may account
for the diminution in the influx of MDSC observed in
the tumor infiltrates of mice treated with MI-319, it is
possible that other factors that are both hypoxia-
inducible and suppressed by p53 will be identified that
might contribute to the anti-angiogenic effects of the
drug.
Our observation that sunitinib treatment increases
MDSC infiltration of RCC xenografts is at odds with
several previous reports showing that the drug limits the
expansion of these cells and enhances immune function
[39-43]. Most of these earlier reports, however, were based
on analyses of peripheral blood or splenocytes. Ko et al,
for example, showed that RCC patients have increased
numbers of MDSC in the peripheral blood and that
sunitinib treatment results in a decline in their numbers
[39]. Sunitinib treatment consistently reduces MDSC
accumulation in the spleens of tumor-bearing mice in
Figure 7 The effects of treatment on α(II) PH, endostatin, and arresten levels in RCC xenografts. A, B). The expression of all three proteins
was induced by sunitinib treatment and levels did not diminish with the onset of drug resistance. C, D). Levels of endostatin and arresten were
increased by treatment with either sunitinib or MI-319 but the inductive effects of the two drugs were not additive. Lanes represent data from
individual tumors for each treatment group.
Figure 6 A). Effect of p53 knockdown on the response of 786-0
xenografts to sunitinib treatment. The expression of a p53 shRNA
markedly reduced the antitumor effect of sunitinib. Each growth
curve represents the mean tumor volume from 6 mice in each
treatment group. B). p53 knockdown blocked the deposition of
endostatin and arresten otherwise induced by sunitinib treatment.
Lysates were from tumors on day 28 after the start of treatment.
Lanes represent data from individual tumors for each treatment
group. Blots were probed for p53, p21, endostatin, arresten
and vinculin.
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MDSC did not extend to the tumor microenvironment,
where MDSC continued to accumulate with the expected
deleterious effect on T cell function, regardless of treat-
ment. These site-specific effects may be attributable to the
cytokine GM-CSF, which is capable of rendering MDSC
resistant to the effects of sunitinib [40].
Our studies suggest that sunitinib can actually increase
the influx of MDSC into tumor tissue in some circum-
stances. This result may be unique to VHL-deficient RCC
and dependent on the severity of the hypoxia induced in
these tumors by VEGF-targeted agents. To the extent that
this is the case, one would expect that these tumors would
abundantly produce SDF-1 and other HIF-dependent
chemokines (which recruit MDSC) in response to
sunitinib treatment. The suppressive effects of sunitinib
on MDSC accumulation and function are thought to be
mediated through the inhibition of STAT3 and c-kit
[41,42]. It is possible that hypoxia-induced chemokine
production within tumor tissue may in some circumstances
trump these inhibitory effects of sunitinib, resulting in
an increase in MDSC infiltration.
Another mechanism by which p53 regulates angiogen-
esis is through the induction of α(II) PH and the depos-
ition of anti-angiogenic collagen fragments (e.g. arresten,
endostatin, canstatin) in the ECM [16-19]. Several previ-
ous studies have in fact suggested that this is one of the
dominant mechanisms by which tumor angiogenesis and
growth are suppressed by p53 [19]. Our data clearly estab-
lish that p53 activation is essential for the deposition of
endostatin and arresten in 786-0 xenografts (Figure 6A)
and in this respect, our results corroborate the results of
Assadian et al, who demonstrated a similar requirement
for p53 in the production of arresten by HCT116 cells
[19]. Despite the absolute requirement for p53, however,
sustained p53 activation does not appear to be essential to
maintain endostatin and arresten levels in RCC xenografts
during sunitinib treatment. We have not been able to
demonstrate a significant decline in endostatin or arresten
levels after the initial induction despite the apparent loss
of p53 transcriptional activity (i.e. the disappearance of
p21
waf1) during treatment. Indeed, endostatin and arresten
levels remain nearly unchanged with the development of
sunitinib resistance, when p21
waf1 is no longer detectable.
Nor have we been able to demonstrate any enhancement
in endostatin or arresten deposition by the addition of
MI-319 to the treatment regimen, although HDM2 antag-
onism is essential for the maintenance of p21
waf1 expres-
sion. Collectively, these data suggest that although the
failure to express α(II) PH and to deposit angiostatic colla-
gen fragments (e.g. endostatin, arresten) in the ECM
might account for the faster growth and more vigorous
angiogenesis observed in p53
(-/-) tumors, changes in
endostatin or arresten levels are not a factor in the
development of sunitinib resistance in p53-WT RCC nor
in the enhanced suppression of angiogenesis and tumor
growth resulting from the concurrent administration of
MI-319 with sunitinib.
We have demonstrated that treatment of mice bearing
RCC xenografts with VEGF-targeted agents results in
p53 activation, the biological effects of which are
quickly undermined with the onset of drug resistance,
possibly due to the induction of the p53 antagonist
HDMX. We have further shown that the HDM2/HDMX
antagonist MI-319 maintains p53 function during treat-
ment and delays/prevents the emergence of resistance.
These data suggest that the evasion of p53 function is
an essential element in tumor escape from the effects of
VEGF-targeted therapy. The effects of MI-319 appear to
be at least in part due to the ability of the drug to
suppress the influx of MDSC into the tumor, which may
in turn be due to its ability to block the production of
chemokines such as SDF-1 that are otherwise induced
in the setting of hypoxia. The potential utility of a
combination of an HDM2 antagonist with sunitinib may
not be limited to RCC. For example, in a recent study
by Henze et al, the HDM2 antagonist Nutlin-3 was
shown to augment the apoptotic response of imatinib-
resistant gastrointestinal stromal tumor (GIST) cell
lines to sunitinib [44]. In this case, however, the effects
o fs u n i t i n i bw e r em o s tl i k e l ya t t r i b u t a b l et oi t sa b i l i t yt o
inhibit c-kit rather than its antiangiogenic effects.
Collectively, these data provide a strong rationale for
the concurrent use of HDM2 antagonists as adjuncts to
VEGF receptor inhibitors in the management of meta-
static RCC and other tumor types.
Materials and methods
Cell lines and reagents. The human RCC cell lines 786-0
and A498 were obtained from ATCC and maintained in
RPMI-1640 (Lonza) and Eagle minimal essential medium
(ATCC), respectively containing 10% fetal bovine serum
(USA Scientific), 2 mM glutamine and 50 μg/ml
gentamycin at 37°C in 5 percent CO2. The MI-319 was
provided by Ascenta Therapeutics (Malvern, PA) and
Sanofi-Aventis (Paris, France).
Western blots
Cells were treated as described in Results and then lysed
in Lysis Solution (Cell Signaling) supplemented with
sodium fluoride (10 μM, Fisher Scientific, Hampton, NH)
and phenylmethylsulfonyl fluoride (100 μg/ml, Sigma-
Aldrich, St Louis, MO). Lysates were fractionated in 8-16%
gradient SDS-polyacrylamide gels as indicated and the
separated proteins were transferred to nitrocellulose. The
blots were probed for the proteins of interest with specific
antibodies followed by a second antibody-horse radish
peroxidase conjugate and then incubated with SuperSignal
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blots were then exposed to Kodak X-Omat Blue XB-1
film. The p21
waf1, noxa, SDF-1, collagen type XVIII
(endostatin) and collagen type IV (arresten) antibodies
were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA); the p53 antibody was purchased from Cell Sig-
naling (Beverly, MA); the HDMX and HDM2 antibodies
were obtained from ABCAM (Cambridge, MA). The
vinculin antibody was obtained from Sigma (St. Louis,
MO). The CD11b antibody conjugated to Alexa 488 and
t h eG r - 1a n t i b o d yc o n j u g a t e dt oA l e x a6 4 7w e r ep u r c h a s e d
from Biolegend (San Diego, CA). The α(II) PH antibody
was obtained from Bethyl Laboratories (Montgomery, TX).
Xenograft model
All animal studies were conducted according to an In-
stitutional Animal Care and Use Committee (IACUC)-
approved protocol at the Beth Israel Deaconess Medical
Center. Six to eight week old athymic nude/beige female
mice (Charles River Labs) were implanted subcutaneously
with 1.0×10
7 RCC cells. When the tumors reached
10 mm in diameter, the mice were divided into 4 treat-
ment groups of 6 mice each and treated daily for 21 days
by gavage with sunitinib (50 mg/kg), MI-319 (200 mg/kg),
sunitinib+MI-319, or saline (control). The doses of
sunitinib [36,45] and MI-319 [46,47] were as previously
reported. Tumors were measured bidimensionally daily.
Tumor tissue from the sacrificed mice was frozen in liquid
N2 for western blot analysis as described in Results or
fixed in formalin for paraffin embedding.
Immunohistochemistry and immunofluorescence
microscopy
The paraffin-embedded tumor tissue was sectioned at 5
microns using a Leica RM 2125 rotary microtome. The
sections were dewaxed at 60°C, serially immersed in
solutions of decreasing alcohol concentration, and then
boiled in 10 mM sodium citrate, pH 6.2, for 30 minutes
to unmask antigens. The tissue was then incubated in
3% hydrogen peroxide for 5 minutes, blocked with 1%
BSA and 5% goat serum, and incubated overnight at 4°C
with an antibody to Ki-67 (Dako, Carpinteria, CA). The
Ki-67 epitope was detected using a biotinylated anti-
mouse Ig antibody and an avidin-horseradish peroxidase
conjugate (Vector Laboratories, Burlingame, CA). Simi-
larly, sections were stained for endothelial cells with an
antibody to CD 31 (ABCAM), followed by a biotinylated
anti-rabbit Ig antibody (Vector Laboratories, Burlingame,
CA). Slides were then counterstained with hematoxylin,
dehydrated, and mounted. Tissue staining was quantitated
using IMAGE Pro 6.0 software (MediaCybernetics, Inc,
Bethesda, MD).
The sections were assayed for apoptosis using the
TUNEL method (Millipore, Billerica, MA) in accordance
with an established protocol [48]. The tissue was hydrated
and treated sequentially with proteinase K and hydrogen
peroxide, and then blocked as described above for the Ki-
67 staining. The sections were then exposed to a solution
containing mixed nucleotides, some of which were
digoxygenin-labeled, and terminal deoxynucleotidyl trans-
ferase (TdT). The slides were developed with an anti-
digoxigenin antibody-peroxidase conjugate and DAB
substrate.
Immunofluorescence microscopy was utilized to image
the infiltration of the CD11b
+/G r - 1
+ MDSC cells with
each paraffin embedded tissue. The protocol followed the
procedure outlined above for Ki-67 and CD31 staining for
dehydration to hydration and unmasking followed by
blocking with 5% normal goat serum in PBS/0.05%
triton ×-100. Antibodies to CD11b antibody conjugated
to Alexa 488 and the Gr-1 antibody conjugated to Alexa
647 were added concurrently at 1:200 dilution in PBS/1%
BSA/0.05% triton ×-100 and incubated overnight at 4°C.
After several washings with PBS, nuclei were stained with
Bisbenzimide H33342 (Alexis Biochemicals, San Diego,
CA). Immunofluoresence microscopy was carried out with
a Nikon TE-2000E microscope at 20× magnification and a
Hamamatsu Orca ER camera. The data was acquired with
Nikon’s NIS-Elements and analyzed with ImageJ software.
Design and construction of tet-inducible p53 shRNA-
transfected 786-0 cell line
To generate 786-0 cells expressing a tetracycline indu-
cible shRNA to p53, the shRNA sequence selector and
shRNA hairpin oligonucleotide sequence designer soft-
ware provided by BD Clontech was used to select opti-
mal sequences. Three shRNAs were generated for each
gene to be silenced. To produce tetracycline-regulable
shRNAs, the oligonucleotides selected were cloned into
the pSingle-tTS-shRNA vector (BD Clontech). This
vector is a tet-on vector. The three shRNA constructs
were transfected as a group into 786-0 cells and stable
transfectants obtained by selection in G418. Clones
were screened individually for inducible expression of
the shRNA (i.e. the suppression of doxorubicin-induced
p53 expression as determined by Western blot) and 2-3
representative clones were selected for each shRNA
based on the degree to which tetracycline exposure
suppressed p53 expression.
Statistical analysis
In vitro data depicted as bar graphs represent mean
values from at least 3 separate experiments +/- standard
error. For most of the studies shown, the significance of
an apparent difference in mean values for any parameter
(e.g. the percent of cells staining with propidium iodide)
was validated by a Student’su n p a i r e dt test and the
difference considered significant if p <0.05. For the
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treatment groups were statistically compared using one-
way ANOVA.
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